Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (151-160 of 531) with videos related to

Pageof 54
Sort By:
Pharmacotherapy|January 1, 1990
The triazole antifungal agents: a review of itraconazole and fluconazoleE M Bailey, D J Krakovsky, M J Rybak
The Journal of Antimicrobial Chemotherapy|September 24, 2014
The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSAKatie E Barber, Brian J Werth, Michael J Rybak
Pharmacotherapy|December 5, 2013
Vancomycin: over 50 years later and still a work in progressMichael J Rybak, John C Rotschafer, Keith A Rodvold
Infectious Diseases and Therapy|September 6, 2015
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive InfectionsJordan R Smith, Karrine D Roberts, Michael J Rybak
Pharmacotherapy|August 21, 2015
The β-Lactams Strike Back: Ceftazidime-AvibactamEvan J Zasowski, Jeffrey M Rybak, Michael J Rybak
Infectious Diseases and Therapy|December 6, 2014
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumanniiKimberly C Claeys, Anna D Fiorvento, Michael J Rybak
American Journal of Hospital Pharmacy|July 1, 1992
Pharmacy-based antimicrobial-monitoring serviceJ R Berman, F K Zaran, M J Rybak
Pharmacotherapy|January 1, 1987
Spiramycin in the treatment of cryptosporidiosisA M Pilla, M J Rybak, P H Chandrasekar
Antimicrobial Agents and Chemotherapy|July 25, 2003
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|June 22, 2006
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
Pageof 54

Showing results (151-160 of 531) with videos related to

Sort By:
Pageof 54
Pharmacotherapy|January 1, 1990
The triazole antifungal agents: a review of itraconazole and fluconazoleE M Bailey, D J Krakovsky, M J Rybak
The Journal of Antimicrobial Chemotherapy|September 24, 2014
The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSAKatie E Barber, Brian J Werth, Michael J Rybak
Pharmacotherapy|December 5, 2013
Vancomycin: over 50 years later and still a work in progressMichael J Rybak, John C Rotschafer, Keith A Rodvold
Infectious Diseases and Therapy|September 6, 2015
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive InfectionsJordan R Smith, Karrine D Roberts, Michael J Rybak
Pharmacotherapy|August 21, 2015
The β-Lactams Strike Back: Ceftazidime-AvibactamEvan J Zasowski, Jeffrey M Rybak, Michael J Rybak
Infectious Diseases and Therapy|December 6, 2014
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumanniiKimberly C Claeys, Anna D Fiorvento, Michael J Rybak
American Journal of Hospital Pharmacy|July 1, 1992
Pharmacy-based antimicrobial-monitoring serviceJ R Berman, F K Zaran, M J Rybak
Pharmacotherapy|January 1, 1987
Spiramycin in the treatment of cryptosporidiosisA M Pilla, M J Rybak, P H Chandrasekar
Antimicrobial Agents and Chemotherapy|July 25, 2003
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|June 22, 2006
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusKimberly D Leuthner, Chrissy M Cheung, Michael J Rybak
Pageof 54